Summary of Significant Accounting Policies - Narrative (Details)				12 Months Ended
	Mar. 15, 2023 USD ($)	Dec. 16, 2020 shares	Mar. 02, 2020 $ / shares shares	Dec. 31, 2024 USD ($) segment shares	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($)	Sep. 30, 2025 USD ($)	Apr. 12, 2024 USD ($)	Jul. 07, 2023 USD ($)
Concentration Risk [Line Items]
Restricted cash				$ 9,000,000
Letter of credit				10,000,000
Cash balances on deposit, exceeded balance insured				278,200,000
Payments to acquire office building	$ 11,500,000				$ 11,500,000
Advertising costs				19,400,000	30,700,000
Sales and marketing expense				$ 18,400,000	29,400,000
Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List Not Disclosed Flag				consolidated statement of operations and comprehensive loss
Common stock warrant liabilities, non-current				$ 0	$ 11,000
Current finance lease liability, extensible enumeration				Other current liabilities	Other current liabilities
Noncurrent finance lease liability, extensible enumeration				Other non-current liabilities
Operating lease impairment					$ 11,500,000	$ 11,500,000
Indirect tax liabilities				$ 14,900,000	11,200,000
Number of operating segments | segment				2
Number of reportable segments | segment				2
Subsequent Event
Concentration Risk [Line Items]
Letter of credit							$ 1,000,000
Letter of Credit
Concentration Risk [Line Items]
Restricted cash				$ 10,000,000.0	10,000,000.0
Note receivable
Concentration Risk [Line Items]
Note receivable				$ 0	$ 2,000,000
Restricted stock units
Concentration Risk [Line Items]
Vesting period (in years)				4 years	1 year
Building
Concentration Risk [Line Items]
Payments to acquire office building	10,500,000
Useful life (in years)				39 years
Land
Concentration Risk [Line Items]
Payments to acquire office building	$ 1,000,000
Big Run Studios
Concentration Risk [Line Items]
Impairment loss					$ 2,900,000
Big Run Studios | Note receivable
Concentration Risk [Line Items]
Note receivable					$ 2,000,000			$ 2,000,000	$ 2,000,000
Sponsor
Concentration Risk [Line Items]
Warrants forfeited (in shares) | shares		250,833
Private Warrants
Concentration Risk [Line Items]
Number of shares issued (in shares) | shares			501,667
Stock sold, price per share (in dollars per share) | $ / shares			$ 30.00
Warrants outstanding (in shares) | shares				226,786	226,786
Common stock warrant liabilities, non-current				$ 0.0	$ 11,000
Public Warrant
Concentration Risk [Line Items]
Warrant exercise price (in dollars per share) | $ / shares			$ 230.00
Class A Common Stock | Private Warrants
Concentration Risk [Line Items]
Number of shares called by each warrant (in shares) | shares			1
Maximum
Concentration Risk [Line Items]
Useful life (in years)				5 years
Minimum
Concentration Risk [Line Items]
Useful life (in years)				3 years
Accounts Receivable | Customer Concentration Risk | Customer One
Concentration Risk [Line Items]
Concentration risk (as a percent)				18.00%	37.00%
Accounts Receivable | Customer Concentration Risk | Customer Two
Concentration Risk [Line Items]
Concentration risk (as a percent)				14.00%	12.00%
Accounts Receivable | Customer Concentration Risk | Customer Three
Concentration Risk [Line Items]
Concentration risk (as a percent)				10.00%	9.00%
Accounts Receivable | Customer Concentration Risk | Customer Four
Concentration Risk [Line Items]
Concentration risk (as a percent)				10.00%